Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Deep Learning Algorithm That Detects ARDS with Expert-Level Accuracy Could Be Game-Changer in COVID-19 Treatment

By HospiMedica International staff writers
Posted on 26 Apr 2021
Researchers have found a solution that could help provide the right care to COVID-19 patients with Acute Respiratory Distress Syndrome (ARDS) which is a life-threatening lung injury that progresses rapidly and can often lead to long-term health problems or death, but can be difficult for physicians to recognize.

A research team at the Michigan Center for Integrative Research in Critical Care (MCIRCC; Ann Arbor, MI, USA) has developed a new artificial intelligence (AI) algorithm that analyzes chest X-rays for ARDS. More...
Many patients who die from COVID-19 die from complications associated with the ARDS which occurs when fluid builds up in the lungs’ air sacs and deprives the organs of the oxygen they need to function.

Accurately interpreting a patient’s chest X-ray is a critical component of diagnosing ARDS. However, studies demonstrate that up to 65% of patients with ARDS are diagnosed late or missed and do not receive evidence-based therapies that improve outcomes. Every day of delay in evidence-based treatment is associated with increased mortality. Thus, there is an urgent need for computational tools that can analyze chest radiology studies to support clinicians with real-time ARDS surveillance and ensure fidelity with evidence-based treatments.

The MCIRCC research team showed that their AI algorithm that analyzes chest X-rays for ARDS could, in fact, identify ARDS findings with higher accuracy than many physicians. It also performed well when it was externally validated in patients from another hospital system. The algorithm they used, a type of machine-learning model called deep convolutional neural networks (CNNs), had 121 layers and seven million parameters.

Using an innovative approach, the team then trained the algorithm to identify common radiologic findings, but not ARDS, on 450,000 chest x-rays from publicly available sources. Then they trained the algorithm to detect ARDS using a unique dataset of 8,000 chest x-ray studies carefully reviewed and annotated for ARDS by Michigan Medicine physicians. This approach is called transfer learning, which has many parallels to how humans learn. Further research is needed to evaluate the impact of the algorithm in a clinical setting, but the team at MCIRCC is confident that it will be game-changer. They envision it will help physicians identify ARDS patients more quickly and accurately, and ensure patients receive evidence-based care.

“In our previous work, we found that physicians have difficulty identifying findings of ARDS on chest X-rays,” said Dr. Michael Sjoding, a pulmonary critical physician at Michigan Medicine and lead author of the study. “Early recognition and treatment are key factors in treating ARDS. Delays can be catastrophic. We now have a highly reliable way to identify ARDS patients, which will also allow us to study them more effectively.”


Related Links:
MCIRCC


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
Half Apron
Demi
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.